A change in judicial deference to the FDA has occurred, potentially impacting the agency's authority. The shift, related to the demise of Chevron deference, may expose the FDA to increased legal challenges, with implications for various areas of regulation, including tobacco and pharmaceuticals. The effects of this change are still being assessed, with several key cases being watched for their potential impact on the FDA's regulatory authority.